Anthera Pharmaceuticals, a biotech that is developing anti-inflammatory therapies for acute coronary syndrome and lupus, will see its quiet period end this Friday, April 9th. On February 28th, the company raised $42 million by offering 6 million shares at $7, below the range of $13-$15. Deutsche Bank acted as the lead manager on the deal.
